论文部分内容阅读
目的探讨KDM2A蛋白在Ⅲ期大肠癌患者的表达及其意义。方法免疫组化检测87例Ⅲ期大肠癌样本(A组)和20例同期非肿瘤性肠黏膜组织手术标本(B组)中KDM2A的表达。随访(53.4±24.3)个月,分析其与临床病理参数及预后的关系。结果 A组KDM2A表达阳性者40例(46.0%);B组KDM2A表达为阴性(P<0.01)。A组组织学低分化、女性和死亡患者KDM2A阳性表达率高于高中分化、男性和存活患者(P<0.05)。A组KDM2A阳性表达者的5年生存率为47.5%,低于KDM2A阴性者的70.2%(P<0.05)。结论 KDM2A参与大肠癌发生、发展,是一个独立的预后参数。
Objective To investigate the expression of KDM2A protein in patients with stage Ⅲ colorectal cancer and its significance. Methods Immunohistochemistry was used to detect the expression of KDM2A in 87 cases of stage Ⅲ colorectal cancer (group A) and 20 cases of non-tumorous intestinal mucosa (group B). Follow-up (53.4 ± 24.3) months, analysis of its relationship with clinicopathological parameters and prognosis. Results Forty cases (46.0%) were positive for KDM2A expression in group A, while negative for KDM2A in group B (P <0.01). In group A, the positive rate of KDM2A in poorly differentiated, female and dead patients was higher than that in high school students, male patients and survivors (P <0.05). The 5-year survival rate of patients with positive expression of KDM2A in group A was 47.5%, lower than 70.2% of patients with negative KDM2A (P <0.05). Conclusion KDM2A is involved in the occurrence and development of colorectal cancer and is an independent prognostic parameter.